Пограничное расстройство личности: идентификация, коморбидность и новые возможности лечения
- Авторы: Зобин М.Л.1
-
Учреждения:
- Центр трансформационной терапии аддикций
- Выпуск: Том LVII, № 2 (2025)
- Страницы: 150-159
- Раздел: Дискуссии
- URL: https://journal-vniispk.ru/1027-4898/article/view/312180
- DOI: https://doi.org/10.17816/nb677346
- EDN: https://elibrary.ru/VYZUFR
- ID: 312180
Цитировать
Аннотация
В статье анализируются диагностические критерии пограничного расстройства личности в рамках DSM-5 и МКБ-11. Сочетание категориальной и размерной диагностической модели повышает её валидность, что соответствует потребностям клинической практики. Одновременно подчёркивается неоднородность и сохраняющаяся концептуальная неопределённость пограничного расстройства. Феноменология коморбидности пограничного и аддиктивного расстройства рассматривается как взаимопроникающая симптоматика, усугубляющая совокупную динамику. Отмечаются сложности диагностики пограничного расстройства личности, когда конституциональная симптоматика маскируется последствиями употребления психоактивных веществ. Приводится краткий обзор современных подходов к лечению пограничного расстройства с акцентом на потенциальных возможностях кетаминовой терапии. Обсуждаются результаты собственного ретроспективного открытого исследования 18 пациентов с двойным (пограничное расстройство личности + расстройство вследствие употребления алкоголя/кокаина) и тройным (пограничное расстройство личности + расстройство вследствие употребления алкоголя/кокаина + депрессия) диагнозом, получавших лечение кетамином. Приводится недельный протокол трёх инфузий кетамина в дозе 0,5–0,75 мг/кг в течение 40 мин с последующей бустерной процедурой через месяц. Обсуждаются предварительные результаты лечения, вполне сопоставимые с эффективностью специализированной психотерапии. Делается вывод о том, что применение кетаминовой терапии позволяет пересмотреть традиционный терапевтический нигилизм в отношении пограничного расстройства личности.
Полный текст
Открыть статью на сайте журналаОб авторах
Михаил Леонидович Зобин
Центр трансформационной терапии аддикций
Автор, ответственный за переписку.
Email: dr.zobin@gmail.com
ORCID iD: 0000-0002-8239-3770
SPIN-код: 2440-1383
кандидат медицинских наук
Россия, Черногория, ДобротаСписок литературы
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington: American Psychiatric Association; 2013. ISBN: 978-0-89042-554-1
- Leichsenring F, Fonagy P, Heim N, et al. Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. 2024;23(1):4–25. doi: 10.1002/wps.21156
- WHO. ICD-11 Clinical descriptions and diagnostic guidelines for mental and behavioural disorders. Geneva: World Health Organisation; 2022. ISBN: 978-92-4-007726-3
- Bach B, Kramer U, Doering S, et al. The ICD-11 classification of personality disorders: a European perspective on challenges and opportunities. Bord Personal Disord Emot Dysregul. 2022;9(1):12. doi: 10.1186/s40479-022-00182-0
- Bohus M, Stoffers-Winterling J, Sharp C, et al. Borderline personality disorder. Lancet. 2021;398(10310):1528–1540. doi: 10.1016/S0140-6736(21)00476-1
- Gunderson JG, Herpertz SC, Skodol AE, et al. Borderline personality disorder. Nat Rev Dis Primers. 2018;4:18029. doi: 10.1038/nrdp.2018.29
- Shah R, Zanarini MC. Comorbidity of borderline personality disorder: current status and future directions. Psychiatr Clin N Am. 2018;41(4):583–593. doi: 10.1016/j.psc.2018.07.009
- Szerman N, Peris L. Personality disorders and addiction disorders. In: el-Guebaly N, Carrà G, Galanter M, editors. Textbook of Addiction Treatment: International Perspectives. Springer, Milano; 2015. Р. 2063–2083. doi: 10.1007/978-88-470-5322-9_120
- Trull TJ, Freeman LK, Vebares TJ, et al. Borderline personality disorder and substance use disorders: an updated review. Borderline Personal Disord Emot Dysregul. 2018;5:15. doi: 10.1186/s40479-018-0093-9
- Stetsiv K, McNamara IA, Nance M, Carpenter RW. The co-occurrence of personality disorders and substance use disorders. Curr Psychiatry Rep. 2023;25(11):545–554. doi: 10.1007/s11920-023-01452-6
- Szerman N, Torrens M, Maldonado R, et al. World association on dual disorders (WADD). addictive and other mental disorders: a call for a standardized definition of dual disorders. Transl Psychiatry. 2022;12(1):446. doi: 10.1038/s41398-022-02212-5
- Maremmani A, Maremmani I. It’s time to admit the existence of a psychopathology specific to addiction. Neurology Bulletin. 2025;57(1):5–11. doi: 10.17816/nb637368
- Chapman J, Jamil RT, Fleisher C, Torrico TJ. Borderline personality disorder. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.
- Trull TJ, Jahng S, Tomko RL, et al. Revised NESARC personality disorder diagnoses: gender, prevalence, and comorbidity with substance dependence disorders. J Pers Disord. 2010;24(4):412–426. doi: 10.1521/pedi.2010.24.4.412
- Parmar A, Kaloiya G. Comorbidity of personality disorder among substance use disorder patients: a narrative review. Indian J Psychol Med. 2018;40(6):517–527. doi: 10.4103/IJPSYM.IJPSYM_164_18
- Jahng S, Trull TJ, Wood PK, et al. Distinguishing general and specific personality disorder features and implications for substance dependence comorbidity. J Abnorm Psychol. 2011;120(3):656–669. doi: 10.1037/a0023539
- Fraser R, Isaif L, Teles D, Laporte L. Personality disorders and addiction disorders. In: el-Guebaly N, Carrà G, Galanter M, Baldacchino AM, editors. Textbook of Addiction Treatment. Springer, Cham; 2021. doi: 10.1007/978-3-030-36391-8_96
- Mulder RT, Horwood LJ, Tyrer P. The borderline pattern descriptor in the International Classification of Diseases, 11th Revision: A redundant addition to classification. Aust N Z J Psychiatry. 2020;54(11):1095–1100. doi: 10.1177/0004867420951608
- Gutiérrez F, Aluja A, Ruiz Rodríguez J, et al. Borderline, where are you? A psychometric approach to the personality domains in the International Classification of Diseases, 11th Revision (ICD-11). Personal Disord. 2023;14(3):355–359. doi: 10.1037/per0000592
- Caspi A, Houts RM, Belsky DW, et al. The p factor: one general psychopathology factor in the structure of psychiatric disorders? Clin Psychol Sci. 2014;2(2):119–137. doi: 10.1177/2167702613497473
- Gluschkoff K, Jokela M, Rosenström T. General psychopathology factor and borderline personality disorder: Evidence for substantial overlap from two nationally representative surveys of U.S. adults. Personal Disord. 2021;12(1):86–92. doi: 10.1037/per0000405
- Sharp C, Wall K. DSM-5 level of personality functioning: refocusing personality disorder on what it means to be human. Annu Rev Clin Psychol. 2021;17:313-337. doi: 10.1146/annurev-clinpsy-081219-105402
- Zanarini MC, Temes CM, Frankenburg FR, et al. Description and prediction of time-to-attainment of excellent recovery for borderline patients followed prospectively for 20 years. Psychiatry Res. 2018;262:40–45. doi: 10.1016/j.psychres.2018.01.034
- Clinical guidelines: Specific personality disorders. 2024–2025–2026 (23.08.24). Approved by the Ministry of Health of the Russian Federation. (In Russ.) URL: http://disuria.ru/_ld/14/1459_kr24F60F61MZ.pdf
- National Institute for Health and Care Excellence. Borderline personality disorder: recognition and management. Clinical guideline. London: National Institute for Health and Care Excellence; 2009. URL: https://www.nice.org.uk/guidance/cg78
- Simonsen S, Bateman A, Bohus M, et al. European guidelines for personality disorders: past, present and future. Borderline Personal Disord Emot Dysregul. 2019;6:9. doi: 10.1186/s40479-019-0106-3
- Cristea IA, Gentili C, Cotet CD, et al. Efficacy of psychotherapies for borderline personality disorder: a systematic review and meta-analysis. JAMA Psychiatry. 2017;74(4):319–328. doi: 10.1001/jamapsychiatry.2016.4287
- Smits ML, Luyten P, Feenstra DJ, et al. Trauma and outcomes of mentalization-based therapy for individuals with borderline personality disorder. Am J Psychother. 2022;75(1):12–20. doi: 10.1176/appi.psychotherapy.20210027
- Setkowski K, Palantza C, van Ballegooijen W, et al. Which psychotherapy is most effective and acceptable in the treatment of adults with a (sub)clinical borderline personality disorder? A systematic review and network meta-analysis. Psychol Med. 2023;53(8):3261–3280. doi: 10.1017/S0033291723000685
- Woodbridge J, Townsend M, Reis S, et al. Non-response to psychotherapy for borderline personality disorder: A systematic review. Aust N Z J Psychiatry. 2022;56(7):771–787. doi: 10.1177/00048674211046893
- Gartlehner G, Crotty K, Kennedy S, et al. Pharmacological treatments for borderline personality disorder: A systematic review and meta-analysis. CNS Drugs. 2021;35(10):1053–1067. doi: 10.1007/s40263-021-00855-4
- Stoffers J, Völlm BA, Rücker G, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;(6):CD005653. doi: 10.1002/14651858.CD005653.pub2
- Pascual JC, Arias L, Soler J. Pharmacological management of borderline personality disorder and common comorbidities. CNS Drugs. 2023;37(6):489–497. doi: 10.1007/s40263-023-01015-6
- Yavi M, Lee H, Henter ID, et al. Ketamine treatment for depression: a review. Discov Ment Health. 2022;2(1):9. doi: 10.1007/s44192-022-00012-3
- Jones JL, Mateus CF, Malcolm RJ, et al. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psychiatry. 2018;9:277. doi: 10.3389/fpsyt.2018.00277
- Dakwar E, Nunes EV, Hart CL, et al. A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology. 2018;142:270–276. doi: 10.1016/j.neuropharm.2018.01.005
- Walsh Z, Mollaahmetoglu OM, Rootman J, et al. Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review. BJPsych Open. 2021;8(1):e19. doi: 10.1192/bjo.2021.1061
- Drozdz SJ, Goel A, McGarr MW, et al. Ketamine assisted psychotherapy: A systematic narrative review of the literature. J Pain Res. 2022;15:1691–1706. doi: 10.2147/JPR.S360733
- Danayan K, Chisamore N, Rodrigues NB, et al. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder. Psychiatry Res. 2023;323:115133. doi: 10.1016/j.psychres.2023.115133
- McIntyre RS, Lipsitz O, Rodrigues NB, et al. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar Disord. 2020;22(8):831–840. doi: 10.1111/bdi.12941
- Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: A midazolam controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. doi: 10.1176/ appi.ajp.2017.17060647
- Lengvenyte A, Olie E, Courtet P. Suicide has many faces, so does ketamine: a narrative review on Ketamine's antisuicidal actions. Curr Psychiatry Rep. 2019;21(12):132. doi: 10.1007/s11920-019-1108-y
- Nandan NK, Soni PK, Parsaik A, Hashmi A. "Esketamine" in borderline personality disorder: a look beyond suicidality. Cureus. 2022;14(4):e24632. doi: 10.7759/cureus.24632
- Rogg H, Avram M, Müller F, et al. Ketamine as a treatment option for severe borderline personality disorder: a case report. J Clin Psychopharmacol. 2023;43(1):64–65. doi: 10.1097/JCP.0000000000001642
- Fineberg SK, Choi EY, Shapiro-Thompson R, et al. A pilot randomized controlled trial of ketamine in borderline personality disorder. Neuropsychopharmacology. 2023;48(7):991–999. doi: 10.1038/s41386-023-01540-4
- Więdłocha M, Marcinowicz P, Komarnicki J, et al. Depression with comorbid borderline personality disorder — could ketamine be a treatment catalyst? Front Psychiatry. 2024;15:1398859. doi: 10.3389/fpsyt.2024.1398859
- Wöller W, Huppertz BJ. Borderline — eine diagnostische Einheit? [Borderline — a diagnostic entity?]. Fortschr Neurol Psychiatr. 1984;52(10):338–345. doi: 10.1055/s-2007-1002031
- Vanicek T, Unterholzner J, Lanzenberger R, et al. Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder. World J Biol Psychiatry. 2022;23(9):715–718. doi: 10.1080/15622975.2022.2031287
- Krupitsky E, Burakov A, Romanova T, et al. Ketamine psychotherapy for heroin addiction: immediate effects and two-year followup. J Subst Abuse Treat. 2002;23(4):273–283. doi: 10.1016/S0740-5472(02)00275-1
- Rothberg RL, Azhari N, Haug NA, Dakwar E. Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. J Psychopharmacol. 2021;35(2):150–158. doi: 10.1177/0269881120970879
- Chiappini S, d'Andrea G, De Filippis S, et al. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study. Eur Neuropsychopharmacol. 2023;74:15–21. doi: 10.1016/j.euroneuro.2023.04.01 145
- Mollaahmetoglu OM, Keeler J, Ashbullby KJ, et al. “This is something that changed my life”: A qualitative study of patients’ experiences in a clinical trial of ketamine treatment for alcohol use disorders. Front Psychiatry. 2021;12:695335. doi: 10.3389/fpsyt.2021.695335
- Nielson EM, May DG, Forcehimes AA, Bogenschutz MP. The psychedelic debriefing in alcohol dependence treatment: illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol. 2018;9:132. doi: 10.3389/fphar.2018.00132
- Hutsebaut J, Bender DS. The clinical utility of the level of personality functioning scale: a treatment perspective. J Psychiatr Pract. 2024;30(6):411–420. doi: 10.1097/PRA.0000000000000822
- Kleindienst N, Jungkunz M, Bohus M. A proposed severity classification of borderline symptoms using the borderline symptom list (BSL-23). Borderline Personal Disord Emot Dysregul. 2020;7(1):11. doi: 10.1186/s40479-020-00126-6
- Unoka Z, Csáky-Pallavicini K, Horváth Z, et al. The Inventory of personality organization: A valid instrument to detect the severity of personality dysfunction. Front Psychiatry. 2022;13:995726. doi: 10.3389/fpsyt.2022.995726
- Gren J, Gorman I, Ruban A, et al. Call for evidence-based psychedelic integration. Exp Clin Psychopharmacol. 2024;32(2):129–135. doi: 10.1037/pha0000684
- Iliakis EA, Ilagan GS, Choi-Kain LW. Dropout rates from psychotherapy trials for borderline personality disorder: a meta-analysis. Personal Disord. 2021;12(3):193–206. doi: 10.1037/per0000453
- Leichsenring F, Sarrar L, Steinert C. Drop-outs in psychotherapy: a change of perspective. World Psychiatry. 2019;18(1):32–33. doi: 10.1002/wps.20588
- Sicorello M, Schmahl C. Emotion dysregulation in borderline personality disorder: A fronto-limbic imbalance? Curr Opin Psychol. 2021;37:114–120. doi: 10.1016/j.copsyc.2020.12.002
- Romeo B, Hermand M, Pétillion A, et al. Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: A systematic review. J Psychiatr Res. 2021;137:273–282. doi: 10.1016/j.jpsychires.2021.03.002
- Varela FJ, Thompson ET, Rosch E. The embodied mind: cognitive science and human experience. MIT press; 1993. 308 p.
- Davidson D. The material mind. Essays on actions and events. New York: Oxford University Press; 2001. 346 p.
- Tyrer P, Mulder R, Kim YR, Crawford MJ. The development of the ICD-11 classification of personality disorders: an amalgam of science, pragmatism, and politics. Annu Rev Clin Psychol. 2019;15:481–502. doi: 10.1146/annurev-clinpsy-050718-095736
Дополнительные файлы
